NIH

May 6, 2021

VUMC to lead national study to treat severe COVID complications

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.

By Bill Snyder
The team studying the regulation of innate immune response includes (front row, from left) Yang Zhao, Antiana Richardson, (back row, from left) John Karijolich, PhD, Xiang Ye and William Dunker.
May 6, 2021

Study finds that regulatory protein prevents signaling that triggers cell death

A protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis prevents the activation of an innate immune response that leads to cell death, Vanderbilt researchers have discovered.

By Leigh MacMillan
May 4, 2021

New strategy to treat brain bleeding

Vasorelaxing peptides could offer a promising therapeutic strategy for reducing the neurological deficits caused by subarachnoid hemorrhage-induced cerebral blood vessel constriction.

By Leigh MacMillan
April 29, 2021

Genetic ancestry and hypertension risk

Racial disparities in hypertension risk are due in part to genetic differences between ancestries, Vanderbilt investigators find in a study of participants in the Million Veteran Program.

By Bill Snyder
April 29, 2021

A compound to counteract aging?

A compound that increases lifespan in yeast is offering clues to pharmacological approaches that might slow the aging process and improve health.

By Leigh MacMillan
April 20, 2021

New therapeutic strategy for leukemia syndrome

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

By Leigh MacMillan
April 19, 2021

VUMC aids national effort to repurpose drugs for COVID-19

Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19.
By Bill Snyder
April 15, 2021

New insights into kidney development

Integrin-linked kinase, a central component of a complex that coordinates cell signaling involved in migration, proliferation and cell death, plays a role in kidney development and epithelial cell function.
By Bill Snyder
April 15, 2021

Arrhythmia culprit: supertrafficking ion channel

Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.
By Leigh MacMillan
April 7, 2021

Study revises understanding of cancer metabolism

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.
By Leigh MacMillan
April 6, 2021

U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC

The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
By Bill Snyder
April 5, 2021

Codeine metabolizer status in clinical practice

Vanderbilt researchers have developed a response score using genetic and clinical information to aid prescribing of the widely used pain medication codeine.
By Leigh MacMillan
April 1, 2021

COVID-19 met with intensive teamwork

Team members serving COVID-19 inpatients were more densely connected, interacting far more than their medical ICU counterparts.
By Paul Govern
1 … 16 17 18 19 20 … 104